Literature DB >> 2951155

The prevention and reversibility of tissue non-enzymatic glycosylation in diabetes.

S McLennan, D K Yue, M Marsh, B Swanson, L Delbridge, T Reeve, J R Turtle.   

Abstract

The time course of non-enzymatic glycosylation (NEG) of liver, kidney, tail collagen, and haemoglobin was studied in diabetic rats. Increased NEG of liver, kidney, and collagen was detectable within 4 weeks of diabetes. The abnormal NEG of liver, kidney, and haemoglobin present after 4 weeks of untreated diabetes could be normalized by 4-8 weeks of intensive insulin therapy given by continuous subcutaneous infusion. However, the same treatment was ineffective in reversing the abnormal NEG and thermal stability of tail collagen. The differences in the development and reversibility of these tissue changes may be due to different tissue turnover rates. Insulin therapy, given from the onset of diabetes, was effective in preventing the development of collagen abnormalities. This suggests that early and vigorous treatment of diabetes is necessary to prevent collagen changes which are potentially irreversible.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2951155     DOI: 10.1111/j.1464-5491.1986.tb00725.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  3 in total

1.  Resolution of diabetic cheiroarthropathy.

Authors:  D M Lister; R A Graham-Brown; A C Burden
Journal:  Br Med J (Clin Res Ed)       Date:  1986-12-13

2.  Glycation of type I collagen selectively targets the same helical domain lysine sites as lysyl oxidase-mediated cross-linking.

Authors:  David M Hudson; Marilyn Archer; Karen B King; David R Eyre
Journal:  J Biol Chem       Date:  2018-08-24       Impact factor: 5.157

3.  Decrease in skin collagen glycation with improved glycemic control in patients with insulin-dependent diabetes mellitus.

Authors:  T J Lyons; K E Bailie; D G Dyer; J A Dunn; J W Baynes
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.